

## **Avian Pathology**




ISSN: 0307-9457 (Print) 1465-3338 (Online) Journal homepage: https://www.tandfonline.com/loi/cavp20

# Efficacy of $\lambda$ -cyhalothrin, amitraz, and phoxim against the poultry red mite *Dermanyssus gallinae* De Geer, 1778 (Mesostigmata: Dermanyssidae): an eight-year survey

Nicola Pugliese, Elena Circella, Giulio Cocciolo, Annunziata Giangaspero, Danijela Horvatek Tomic, Tana Shtylla Kika, Anna Caroli & Antonio Camarda

To cite this article: Nicola Pugliese, Elena Circella, Giulio Cocciolo, Annunziata Giangaspero, Danijela Horvatek Tomic, Tana Shtylla Kika, Anna Caroli & Antonio Camarda (2019): Efficacy of  $\lambda$ -cyhalothrin, amitraz, and phoxim against the poultry red mite *Dermanyssus gallinae* De Geer, 1778 (Mesostigmata: Dermanyssidae): an eight-year survey, Avian Pathology, DOI: 10.1080/03079457.2019.1645295

To link to this article: https://doi.org/10.1080/03079457.2019.1645295



Publisher: Taylor & Francis & Houghton Trust Ltd

**Journal:** Avian Pathology

**DOI:** 10.1080/03079457.2019.1645295



Efficacy of  $\lambda$ -cyhalothrin, amitraz, and phoxim against the poultry red mite *Dermanyssus* gallinae De Geer, 1778 (Mesostigmata: Dermanyssidae): an eight-year survey

Nicola Pugliese<sup>1</sup>, Elena Circella<sup>1</sup>, Giulio Cocciolo<sup>1</sup>, Annunziata Giangaspero<sup>2</sup>, Danijela Horvatek Tomic<sup>3</sup>, Tana Shtylla Kika<sup>4</sup>, Anna Caroli<sup>1</sup>, Antonio Camarda<sup>1</sup>\*

- <sup>1</sup> Department of Veterinary Medicine, University of Bari "Aldo Moro", Sp per Casamassima Km 3, 70010 Valenzano, Bari, Italy
- <sup>2</sup> Department of Science of Agriculture, Food and Environment, Via Napoli 25, University of Foggia, Foggia, Italy
- <sup>3</sup> Department of Poultry Diseases with Clinic, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia
- <sup>4</sup> Department of Veterinary Public Health, Faculty of Veterinary Medicine, Agriculture University of Tirana, Tirana, Albania

\*Corresponding author, email: antonio.camarda@uniba.it

Acknowledgment

The study was carried out within the EU COST Action FA1404 "Improving current understanding and research for sustainable control of the poultry red mite *Dermanyssus gallinae* (COREMI)".

#### **Abstract**

*Dermanyssus gallinae* (De Geer, 1778) is a major problem for the poultry industry worldwide, as it negatively affects virtually all kinds of rearing systems. Therefore, the control of infestation has become a routine process, and its economic cost is constantly increasing. Until now, most of the control strategies rely on the use of synthetic chemical drugs, but their efficacy is often questioned by the emergence and diffusion of resistant mite populations.

All those considering, the efficacy of  $\lambda$ -cyhalothrin, amitraz, and phoxim has been verified by testing them against 86 mite populations collected from the same number of poultry farms in Italy from 2008 to 2015. Assays were performed according to the filter paper method using the recommended, half, quarter, double and quadruple doses.

Results showed that phoxim and amitraz were the most effective acaricides (median efficacy 80.35% and 80.83%, respectively), but amitraz exhibited a sharp fall in its efficacy during 2011 and 2012, while phoxim maintained its effectiveness high up to 2015, when it dropped, too. Overall median efficacy of  $\lambda$ -cyhalothrin was 58.33%. Data also highlighted the importance of the use of the right concentration emerged, as an increase in dosage was not always useful against resistant populations, while its reduction also diminished its efficacy, simultaneously increasing the risk for the development of resistance.

**Keywords:** *Dermanyssus gallinae*, red mite, susceptibility, Italy,  $\lambda$ -cyhalothrin, amitraz, phoxim

#### Introduction

The poultry red mite (PRM) *Dermanyssus (D.) gallinae* (De Geer, 1778) (Mesostigmata: Dermanyssidae) is a hematophagous mite universally considered a major ectoparasite of poultry, whose infestations are reported from all over the world (Sigognault-Flochlay *et al.*, 2017). Recently, infestations by PRM have also been recorded in North America, despite that area was often considered not affected by *D. gallinae* but by *Ornithonyssus sylviarum* (Tomley & Sparagano, 2018). In Europe, where the presence of PRM has been recorded since decades, the large majority of poultry farms of laying hens and breeders is infested by *D. gallinae*, independently of the production systems (enriched cages, barns, free-range, organic or backyard) (Sparagano *et al.*, 2009).

Poultry red mites usually produce detrimental effects on health and welfare of infested flocks up to determine an increase in mortality whenever infestation level becomes very high (Kilpinen *et al.*, 2005; Mul *et al.*, 2009). In the last years, human infestations by *D. gallinae* have been more frequently reported. Beside the well-established risk that it represents for poultry operators (Cafiero *et al.*, 2011), urban cases are being increasingly recorded (Cafiero *et al.*, 2008; Cafiero *et al.*, 2018; Navarrete-Dechent & Uribe, 2018).

Further concerns are raised by the association between D. gallinae and a number of pathogens, such as  $Erysipelothrix\ rhusiopathiae$  (Chirico  $et\ al.$ , 2003),  $Chlamydia\ psittaci$  (Circella  $et\ al.$ , 2011), Tsukamurella spp. (Hubert  $et\ al.$ , 2017),  $Coxiella\ burnetii$  and  $Borrelia\ burgdorferi$  (Raele  $et\ al.$ , 2018). Moreover, it has been found involved in the transmission of  $Salmonella\ enterica$  subsp.  $enterica\ ser$ . Enteritidis (Valiente Moro  $et\ al.$ , 2007) and Gallinarum (Pugliese  $et\ al.$ , 2018). Consequently, D. gallinae has a heavy impact on the poultry system from an economic point of view, too. It has been estimated that the infestation costs  $0.60\ \mbox{\ensuremath{\in}}\ per\ hen\ per\ year$ , a sum that includes  $0.45\ \mbox{\ensuremath{\in}}\ for\ productivity\ loss\ and\ 0.15\ \mbox{\ensuremath{\in}}\ for\ treatments\ (Sigognault-Flochlay\ et\ al.$ , 2017). In fact, the management of PRM infestation has become a routine process in intensive poultry farms. To date, synthetic acaricides are still the most used drugs for the control of the PRM

infestation, despite several alternative methods have been developed in the last years (reviewed in Sparagano et al., 2014). However, very few treatments are authorized for being administered in poultry farms. Among them, phoxim, an organophosphate, and fluralaner, an isoxazolinesubstituted benzamide derivative, are the only substances authorized for being used in presence of animals in most European Countries, along with Spinosad (Sigognault-Flochlay et al., 2017) Brauneis et al., 2018), a mixture of active metabolites produced by the actinobacterium Saccharopolyspora spinosa (Kirst, 2010). However, the scandal of summer 2017, when the illegal use of fipronil in poultry farms was uncovered in several European countries (Schuetze, 2017), brought to the public opinion the illicit use of unallowed substances, despite the fact that the scientific community was already suspecting that such practices had already been adopted. In fact, residues of pyrethroids and carbaryl were repeatedly detected in chickens (Marangi et al., 2012). Pyrethrins and pyrethroids have been widely used against pests in pets and industrial animal farms since many decades (Beugnet & Franc, 2012), but another source of concern was the potential use of amitraz, a substance belonging to the class of the formamidines, which is still intensively used in veterinary medicine for the treatment of ectoparasitoses in cattle, swine, sheep, and dog (Padula et al., 2012).

Apart from the noticeable implications in term of food contamination and public health, the abuse or misuse of acaricides may also enhance the emergence and diffusion of resistant mite populations (FAO, 2012). In fact, drug resistant populations of *D. gallinae* are being detected even more frequently, posing a further problem to farmers and, directly or indirectly, to all stakeholders of the poultry system (Sigognault-Flochlay *et al.* 2017). The World Health Organization defined the pest resistance as 'an inherited characteristic that imparts an increased tolerance to a pesticide, or a group of pesticides, such that the resistant individuals survive a concentration of the compound(s) that would normally be lethal to the species' (WHO Expert Committee on Vector Biology and Control, 1992). Nowadays, the emergence and spread of resistant pest populations is still a major problem worldwide (Sparks & Nauen, 2015), which impacts on wide areas of human and veterinary

medicine and agriculture. In this scenario, *D. gallinae* does not represent an exception, as the presence of PRM populations resistant to one or more acaricide has been reported since 1985 (Zeman & Železný, 1985) up to the present time (Thomas *et al.*, 2018).

In the light of those considerations, the present study analyzes the trend in the acaricide susceptibility of PRM populations collected from industrial poultry farms in Italy during an eight-year period. In particular, susceptibility to  $\lambda$ -cyhalothrin (a pyrethroid), amitraz and phoxim was evaluated in order to verify possible fluctuations in the efficacy of acaricide drugs authorized and unauthorized for being administered in the poultry farms.

#### Materials and methods

*Mite populations* 

Mites were collected from industrial poultry farms all across Italy since 2008 to 2015. The samples were sent in blind to the facilities of the Avian Disease Unit of the Department of Veterinary Medicine of the University of Bari. All samples were shipped in refrigerated boxes and, upon arrival, mites were starved at room temperature in 5% CO<sub>2</sub> for five days. After starvation, the viability of mites was visually inspected and groups with less than approximately 50% of live mites were excluded from the investigation. Overall, 86 mite populations, collected from the same number of poultry farms, were tested in this study (Tab. 1).

Before performing assays, 10 mites from each sample were randomly selected and morphologically inspected to confirm the *D. gallinae* identification according to the keys of Varma (1993) and Baker

Efficacy test

(1999).

Mites were tested against  $\lambda$ -cyhalothrin (Oxyfly<sup>®</sup> 10 CS, Novartis Animal Health, Basel, Switzerland), amitraz (TakTik125<sup>®</sup>, Farmaceutici Gellini, Aprilia, Italy) and phoxim (ByeMite<sup>®</sup>, Bayer Animal Health, Leverkusen, Germany).

The drug efficacy was assessed by the filter paper technique as described by Thind & Muggleton (1998) with slight modifications. Specifically, two pieces of filter papers were impregnated with 200 µl of acaricide solution; then 20 mites were collected and distributed by using a small brush on the filter paper. The first paper piece was covered by the second, and they were both tightened between two plastic enclosing layers, sealed with vinylic glue. Once prepared, cells were incubated at 20 °C and 60% relative humidity for 24 h; afterward, they were opened and live and dead mites were counted by the aid of a stereomicroscope. Moribund mites were considered inactive, and therefore dead. Control cells were assembled with water instead of acaricide solution. Each assay and the relative control test was performed in triplicate.

Mites were exposed to five different concentrations of acaricides. The field concentration (1X) was defined according to the pesticide label. Namely, 1X  $\lambda$ -cyhalothrin was 0.5 g/L, and 1X phoxim was 2 g/L. Since amitraz was not labeled for poultry, and different concentrations were reported for bovine (0.25 g/L), swine (0.5 g/L) and sheep (0.5 g/L), the higher dosage was considered (0.5 g/L). Considering that 7 cm<sup>2</sup> of paper were impregnated with 200  $\mu$ L of solution, 1X concentration corresponded to 0.14 g/m<sup>2</sup> for  $\lambda$ -cyhalothrin and amitraz, and 0.57 g/m<sup>2</sup> for phoxim.

The other tested concentrations were: two-fold (2X, specifically 1 g/L  $\lambda$ -cyhalothrin, 1 g/L amitraz and 4 g/L phoxim), four-fold (4X, specifically 2 g/L  $\lambda$ -cyhalothrin, 2 g/L amitraz and 8 g/L phoxim), half (0.5X, specifically 0.25 g/L  $\lambda$ -cyhalothrin, 0.25 g/L amitraz and 1 g/L phoxim), and one quarter (0.25X, specifically 0.125 g/L  $\lambda$ -cyhalothrin, 0.125 g/L amitraz and 0.5 g/L phoxim) the field concentration. Those specific concentrations were chosen because of their proximity to those potentially applied in field.

For each group of three replicates, the mean and the 95% confidence interval (CI) were calculated. Whenever the CI was greater than 2% of the mean value, the group of data was discharged.

The percent efficacy was calculated according to Abbott's formula (Abbott, 1925), modified as follows to consider the mean of the three replicates.

$$E = \frac{\text{(mean live mites in control cells - mean live mites in test cells)}}{\text{mean live mites in control cell}} \times 100$$

When mortality was greater than 20% in the control group, the test was rejected (WHO, 2009).

#### Statistical analysis

The gathered efficacy data were grouped and compared by acaricide, by year, by four-year period and by concentration. Furthermore, five efficacy classes (EC), namely 0-20%, 21-40%, 41-60%, 61-80%, 81-100%, were established and mite populations were allocated in them according to the interval where their efficacy fell.

Populations included in the 81-100% and 61-80% EC were considered highly susceptible and susceptible, respectively, those included within the 41-60% EC were considered intermediate, those falling within 0-20% and 21-40% EC were considered highly and moderately resistant, respectively. Shapiro-Wilk test was applied to all groups of data to ascertain their normal distribution, with  $\alpha$ -level for rejecting the null hypothesis equal to 0.05. Since the great majority of data were non-normal distributed, medians and their respective 95% CI were calculated. Comparisons among groups were performed by using the nonparametric, two-tailed Mann-Whitney U test. The ECs were compared by calculating by using two-tailed Fisher's exact test. In both cases, differences were considered significant when P < 0.05

#### Results

Considering the entire period of the survey and the field concentration (Tab. 2), the  $\lambda$ -cyhalothrin was found to be the less effective drug, with an overall median efficacy of 58.33% (CI: 48.33-68.33%). The efficacy of amitraz and phoxim was significantly (P < 0.001, Tab. S8) higher when compared to  $\lambda$ -cyhalothrin, as they killed 80.33% (CI: 71.25-88.33%) and 80.35% (CI:75.00-91.67%) of mites, respectively, without significant (P = 0.523, Tab S8) difference between them.

All statistical analyses were performed in R (R Core Team, 2018).

Such a trend was confirmed by analyzing the ECs (Tab. 3), because the distribution for amitraz and phoxim was right-skewed toward the higher efficacy classes, while the central value for  $\lambda$ -cyhalothrin fell into the central class (41-60%) (Fig. S1).

Fisher's exact test confirmed the significance of the differences in the distribution (P < 0.001 and P = 0.001, respectively).

When the 4-year periods were considered, the efficacy of  $\lambda$ -cyhalothrin and amitraz was significantly lower (P = 0.002 and P = 0.001, respectively, Tab. S8) in the tested mite populations during the 2012-2015 period with respect to the previous one (Tab.2). The EC distribution reflected this trend, as a marked shift was observed from susceptibility to high and moderate resistance to  $\lambda$ -cyhalothrin and amitraz (P = 0.020 and P = 0.003, respectively, Tab. 3, Tab. S8, Fig. S2). Neither median efficacy, nor EC distribution changed significantly for Phoxim (P = 0.436 and P = 0.283 between 2008-2011 and 2012-2015, respectively).

Those facts indicated that phoxim and amitraz efficacies against the tested populations were comparable during the first four-year period (P = 0.293, Tab. S8), but not during 2012-2015 (P = 0.020, Tab S8). Considering the EC distribution for phoxim, no evident changes were observed, as the number of resistant and susceptible populations remained roughly the same (P = 0.283, Tab. 3, Tab. S8).

The analysis of annual trends added new elements (Fig. 1). While in 2008 and 2009 no amitraz-resistant populations were detected, 4.55% of the mite populations tested in 2010 resulted moderately resistant (Tab. 3). In the same years, the median efficacy of phoxim did not vary significantly (Tab. 2) but, in 2010, 4.17% of the tested mite populations were moderately resistant and 8.33% were highly resistant (Tab 3).

During 2011 efficacy of amitraz against tested populations decreased from 87.50% (CI: 67.50-95%) to 67.92% (CI: 51.67-91.84%) with enough statistical relevance (P = 0.051, Tab. 2, Tab. S8). Median efficacy of both  $\lambda$ -cyhalothrin and phoxim did not vary significantly in 2011 with respect to

2010 (P = 0.696 and P = 0.774, respectively, Tab. 2, Tab. S8), and neither did their EC distribution (P = 0.829 and P = 1, respectively, Tab. 3, Tab. S8).

The mite populations tested during 2012 resulted more resistant to  $\lambda$ -cyhalothrin and amitraz, making the efficacy of such drugs drop (P = 0.015 and P = 0.023, respectively, Tab. 2, Tab. S8). Specifically, 83.33% of the tested mite populations were moderately to highly resistant to  $\lambda$ -cyhalothrin, and 42.86% of them were resistant (moderately or highly) to amitraz. No mite population was found highly susceptible to the latter acaricide (Tab. 3). Contrarily, the median of the phoxim killing rate did not vary significantly (P = 0.574, Tab. S8) in 2012 if compared to 2011. No population was found highly resistant to phoxim.

During 2013, the recorded efficacy of the  $\lambda$ -cyhalothrin and amitraz numerically improved. In particular, the latter returned, in terms of killing rate, at a comparable level with phoxim (P = 0.575, Tab. S8).

Mite populations collected during 2014 were neither intermediate, nor resistant to phoxim, and 88.89% was highly susceptible and 11.11% susceptible (Tab. 3). Considering that the efficacy of  $\lambda$ -cyhalothrin and amitraz did not vary significantly with respect to the previous year (P = 0.689 and P = 0.859, Tab. S8), phoxim resulted to be the most effective drug (P = 0.005 against  $\lambda$ -cyhalothrin and P = 0.025 against amitraz, Tab. 2, Tab. S8) against the tested populations.

However, during 2015, the phoxim efficacy significantly (P = 0.007) fell to 45% (CI: 3.89-76.67%). Only 40% of the tested mite populations resulted to be susceptible or highly susceptible to the acaricide, with a significant (P = 0.023, Tab. S8) discrepancy with the data of the previous year. Remarkably, no significant difference was observed between phoxim and  $\lambda$ -cyhalothrin efficacy (P = 1.000, Tab. S8).

Drug efficacy in relation to the concentration

The relation between the concentration of drugs and their efficacy was variable. Considering all the tested mite populations, the 2- and 4-fold increase of  $\lambda$ -cyhalothrin (Tab. S1) concentration did not significantly improve its efficacy (P = 0.288 and P = 0.212, respectively, Tab. S8), against the tested populations, as well as the 2-fold reduction (P = 0.207, Tab. S8). Only when diluted four times,  $\lambda$ -cyhalothrin resulted significantly less effective (P = 0.004, Tab. S8).

Instead, the concentration considerably affected amitraz activity (Tab. S2), as its killing rate increased to median values of 90.00% (CI: 85.00-95.00%) and 96.67% (CI: 91.67-98.33%) when the field concentration was doubled and quadruplicated, respectively, and it decreased to 66.67% (CI: 56.67-75%) and 60.00% (CI: 48.33-70.00%) when concentration was 2- and 4-fold reduced, respectively. Statistical significance of such differences was always high (P = 0.049, P < 0.001, P = 0.004 and P < 0.001, respectively, Tab. S8). However, in 2012, when amitraz efficacy dropped to the minimum point, the increase in concentration did not improve mortality rate of mites, as medians were 31.67% (CI: 5.00-90.00%) and 33.33% (CI: 16.97-91.67%) at 2X and 4X concentrations, respectively (P = 0.443 and P = 0.609, Tab S2, Tab. S8).

Conversely, only the quadruplication of phoxim concentration significantly (P = 0.039, Tab. S8) improved its efficacy (Tab. S3) from 80.35% (CI: 75.00-91.67%) to 90% (CI: 81.67-98.33%). When phoxim concentration was reduced to 0.5X and 0.25X, its efficacy was significantly reduced to 72.50% (CI: 61.67-80.00%) and 62.91%, (CI: 56.67-72.50%) with P = 0.025 and P < 0.001, respectively (Tab. S8). Also in this case, in 2015, when the tested populations were more resistant to phoxim, no significant efficacy improvement was observed when concentration was doubled and quadrupled (P = 0.421 and P = 0.841, respectively, Tab. S3, Tab. S8).

By analyzing the four-year periods, no remarkable association was found between susceptibility trends and variations in concentration. However, it is noteworthy that, during the period 2012-2015, when phoxim activity was the highest among the three tested drugs, the efficacy of 2X and 4X amitraz concentrations were comparable to 1X phoxim (P = 0.535 and P = 0.103, Tab S2, Tab. S3, Tab. S8).

#### **Discussion**

Results from this investigation underlined that the detection of resistant mite populations was a common issue that pertains to all tested acaricides. In fact, two out of the three tested drugs, namely λ-cyhalothrin and amitraz, exhibited a significant decrease in efficacy against the populations collected during the four-year period 2012-2015, especially with respect to those from 2008-2011. Phoxim effects were more constant in time, but highly resistant populations were detected in 2015. The most remarkable contrast was observed for amitraz, which killed more than 80% of mites in 61.82% of populations during the first four-year period but it inactivated less than 80% of mites in 74% of populations during the next four years.

The decrease in efficacy of  $\lambda$ -cyhalothrin was equally sizeable, but less evident because of the low susceptibility of the tested populations since the first years of investigation. On the other side, the phoxim killing rate remained substantially constant in the two four-year periods even considering the drop observed in 2015.

There are some hypotheses for those (trends). It is well recognized that the emergence and spread of resistant population are largely due to the abuse or misuse of drugs, which exert a selective pressure that promotes the survival of resistant individuals (FAO, 2012; Coles & Dryden, 2014). It is no accident that λ-cyhalothrin exhibited the lowest efficacy towards PRM, as it belongs to the pyrethroid family, one of the first insecticide classes. Pyrethroids, such as λ-cyhalothrin and bifenthrin, were largely used in poultry farms to fight the house fly *Musca domestica* L. (Abbas *et al.*, 2016), and this may have contributed to select resistant individuals of *D. gallinae*, too. This could account for the early rise of resistant *D. gallinae* populations, which was firstly documented more than 20 years ago (Beugnet *et al.*, 1997) and it has been repeatedly reported from mites collected in poultry farms (Nordenfors *et al.* 2001; Marangi *et al.*, 2009; Thomas *et al.* 2018). A similar trend was observed for *O. sylviarum* populations collected in the field in California (Mullens *et al.*, 2017).

Data from amitraz are more controversial. An early report found PRM quite tolerant to amitraz (Fletcher & Axtell, 1991), while Marangi et al. (2009) found amitraz so effective to kill 100% of mites belonging to different field populations. Similarly, data from this study evidenced very low resistance levels up to 2011, but, during 2011 and 2012, the proportion of resistant groups raised, whereas susceptible and highly susceptible populations declined. This may indicate that D. gallinae recurrently came in contact with amitraz between the end of the 2000s and the beginning of the 2010s, perhaps because of its illicit use as an acaricide in poultry farms. The unauthorized administration of amitraz in poultry has often been suspected but, to our knowledge, no investigation was carried out to verify it, at least in the years covered by this investigation. Indirect evidence may be inferred by the detection of resistance in the cattle ticks Boophilus microplus (Li et al., 2004). Amitraz is largely used in cattle and a reduction in susceptibility of their ectoparasites is expected. Conversely, if amitraz were not applied in poultry, it would be unusual to find resistant populations, as it has been reported that amitraz resistance is uncommon in absence of selective pressure (Jonsson & Hope, 2007). As a partial confirmation of such a hypothesis, there is the recent detection of amitraz residues in two samples of eggs from Italy (European Food Safety Authority et al., 2018). In the same report, fipronil was detected, too. Previously, residuals deriving from other acaricides, such as carbamates, organophosphates, and pyrethroids, were found in poultry products (Ivey, et al., 1984; Szerletics-Turi et al., 2000; Marangi et al., 2012). On aggregate, those data suggest that the illegal use of unapproved pesticides could have sometimes been practiced by farmers, thus contributing to the emergence of resistant D. gallinae populations. It should be underlined the only authorized acaricides for being used in Italy in presence of hens are phoxim (since 2009), spinosad (since 2011) and, more recently, fluralaner. Other drugs, such as amitraz and fipronil, are not labeled for being applied in poultry, due to their toxicity and their residual activity. Additionally, authorization for the use of carbaryl, employed in the past, had been retired in 2007, but the retrieval of residuals of amitraz or carbaryl (Marangi et al., 2012) in aviary products from

Italy let us hypothesize that some farmer was still using it during the years covered by this investigation.

In the light of those considerations, it is tempting to speculate that the sudden decline of amitraz efficacy during 2011 and 2012 might be consequent to a selection process caused by repeated contacts with amitraz, probably inappropriately dispensed. In fact, it is reasonable to assume that dosing, application mode, and administration schedule might be improperly, or at least empirically, devised when unauthorized drugs were handled.

Conversely, out of the three tested drugs, phoxim was the only one authorized for being used in presence of animals in poultry farms of Italy, and its operating procedures were adequately conceived and set up, especially in terms of dosage and administration schedule. This fact may have helped to keep low the proportion of resistant groups of *D. gallinae*, insomuch that less susceptible populations have been recently detected (Thomas *et al.*, 2018). In this investigation, phoxim-resistant populations were only found in 2015, and it is possible that factors other than contacts with acaricides should be intervened.

A list of elements affecting the susceptibility of pest was scrutinized by the Food and Agriculture Organization of the United Nations (FAO, 2012), which grouped them into three major categories: biological (i.e. population size, reproductive potential, dispersal, pesticide metabolism, number of target sites of pesticides, host range, etc.), genetic (occurrence of resistance genes, resistance mechanisms, fitness of resistant individuals, cross-resistance, past selection, etc.) and operational (activity spectrum of the pesticide, pesticide application rate, application coverage, treatment frequency, etc.). By matching those elements to the known biologic and physiologic features of *D. gallinae*, it is clear that the potential for resistance development is very high, as PRM is characterized by a very high population size, high reproductive potential, great dispersal capability, and a relatively wide potential host range (George *et al.*, 2015). On the other side, most of the substances tested in this study are active against a specific target site, as well as many commercially available drugs. Specifically, pyrethroids and DDT target the sodium channels, carbamates, and

organophosphates are directed against acetylcholinesterase (David *et al.*, 2013), and amitraz binds the octopamine receptor (Beugnet & Franc, 2012). Potentially, their specificity is an important potential factor for the emergence of resistant mites.

Considering that those factors cannot be directly modified, the proper management acquires greatrelevance to the control of the infestation. Among operational aspects, the pesticide application rate is one of the most important. According to FAO (2012), if pesticides are used following the label instructions, then the risk of resistance development is lower because heterozygotes (assumed that the potential resistant genes are incompletely dominant) are killed, while they might survive if the application rate is below the recommended dose. On the other side, if the pesticide is applied at higher doses than required, few homozygous resistant individuals may survive and reproduce, biasing the selection process toward the more resistant mites and thus producing less susceptible populations. The herein collected data about the relation between drug efficacy and concentration strongly suggest that resistant populations were not affected even at higher concentrations, letting infer that they might be composed of homozygous individuals, resistant to high levels of drugs. In particular, the activity of  $\lambda$ -cyhalothrin, whose efficacy was generally low, was not affected by its concentration, as it resulted more effective against D. gallinae populations only when its concentration was increased four times. Contrarily, amitraz was much more influenced by the concentration, as resistant populations were usually killed when it was administered at double or quadruple concentration. Notewhortily, in 2012, when most of the tested populations resulted resistant or, at least, intermediate, the rise in concentration was not as equally effective, probably because they had yet developed high resistance levels. Similar considerations may be replicated for phoxim. Its efficacy was found to be directly related to its dosage, despite the label concentration was usually effective enough to kill more than 80% of mites. However, even for phoxim, data of 2015 showed that no significant effects were obtained by increasing the concentration, as highly resistant populations were developed.

Apart from this exception, it is clear that the label concentration of phoxim was actually the most effective, underlining the pivotal role of the preliminary studies aimed to assess the right dose to be administered, insomuch that every variation in concentration becomes useless or even counterproductive.

All those considering, it appears evident that only integrated management (Tomley & Sparagano) 2018) makes possible an effective control of the *D. gallinae* infestation, also contributing to maintaining low the risk of emergence of resistant mite populations. This approach is aimed to find the correct equilibrium among all factors that act in a poultry farm by, among other, implementing good hygiene practices, avoiding overcrowding, controlling carefully the environmental conditions (i.e. light, humidity and temperature) and adopting a pest control strategy that would alternate more than one synthetic drug and other natural acaricides. A major limitation consists in the small number of available and authorized substances that could be used against *D. gallinae* in poultry farms. Fortunately, research is providing some encouraging results. For example, fluralaner was recently authorized for being used in presence of animals (Brauneis *et al.*, 2018), and interesting data are deriving from tests with the neem oil, an essential oil that has been found active against *D. gallinae* (Camarda *et al.*, 2018). Therefore, the range of available products is widening, and this may encourage stakeholders to adopt well-differentiated strategies for fighting *D. gallinae*, in an effort to reduce infestation, prevent the emergence of resistance and, even, protect the environment by keeping to a minimum the introduction of hazardous substances.

#### **Disclosure statement**

All authors declare no conflict of interests.

#### References

Medicine, 68, 628.

Abbas, N., Shah, R.M., Shad, S.A., Iqbat, N. & Razaq, M. (2016) Biological trait analysis and stability of lambda-cyhalothrin resistance in the house fly, *Musca domestica* L. (Diptera: Muscidae). *Parasitology Research*, 115, 2073-2080.

Abbott, W.S. (1925) A method of computing the effectiveness of an insecticide. *Journal of Economic Entomology*, 18, 265-267.

Baker, A.S. (1999) *Mites and Ticks of Domestic Animals: An Identification Guide and Information Source*. London: The Natural History Museum, The Stationery Office.

Beugnet, F., Chauve, C., Gauthey, M. & Beert, L. (1997) Resistance of the red poultry mite to pyrethroids in France. *Veterinary Record*, 140, 577-579.

Beugnet, F. & Franc, M. (2012) Insecticides and acaricides molecules and/or in combination to prevent pet infestation by ectoparasites. *Trends in Parasitology*, 28, 267-279.

Brauneis, M.D., Zoller, H., Williams, H., Zschiesche, E. & Heckeroth, A.R. (2018) The acaricidal speed of kill of orally administered fluralaner against poultry red mites (*Dermanyssus gallinae*) on laying hens and its impact on mite reproductions. *Parasites & Vectors*, 10, 594.

Cafiero, M.A., Camarda, A., Circella, E., Santagada, G., Schino, G. & Lomuto, M. (2008) Pseudoscabies caused by *Dermanyssus gallinae* in Italian city dwellers: a new setting for an old dermatitis. *Journal of the European Academy of Dermatology and Venereology*, 22, 1382-1383. Cafiero, M.A., Galante, D., Camarda, A., Giangaspero, A. & Sparagano, O. (2011) Why dermanyssosis should be listed as an occupational hazard. *Occupational and Environmental* 

Cafiero, M.A., Viviano, E., Lomuto, M., Raele, D.A., Galante D. & Castelli, E. (2018) Dermatitis due to Mesostigmatic mites (*Dermanyssus gallinae*, *Ornithonyssus [O.] bacoti*, *O. bursa*, *O. sylviarum*) in residential settings. *Journal of the German Society of Dermatology*, 16, 904-906.

Camarda, A., Pugliese, N., Bevilacqua, A., Circella, E., Gradoni, L., George, D., Sparagano, O. & Giangaspero, A. (2018) Efficacy of a novel neem oil formulation (RP03<sup>TM</sup>) to control the poultry red mite *Dermanyssus gallinae*. *Medical and Veterinary Entomology*, 32, 290-297.

Chirico, J., Eriksson, H., Fossum, O. & Jansson, D. (2003) The poultry red mite, *Dermanyssus gallinae*, a potential vector of *Erysipelothrix rhusiopathiae* causing erysipelas in hens. *Medical and Veterinary Entomology*, 17, 232-234.

Circella, E., Pugliese, N., Todisco, G., Cafiero, M.A., Sparagano O.A. & Camarda, A. (2011)

Chlamydia psittaci infection in canaries heavily infested by Dermanyssus gallinae. Experimental and Applied Acarology, 55, 329-338.

Coles, T.B. & Dryden, M.W. (2014) Insecticide/acaricide resistance in fleas and ticks infesting dogs and cats. *Parasites & Vectors*, 7, 8.

David, J.-P., Ismail, H.M., Chandor-Proust, A. & Paine M.J.I. (2013) Role of cytochrome P450s in insecticide resistance: impact on the control of mosquito-borne diseases and use of insecticides on Earth. *Philosophical Transactions of the Royal Society of London. Series B Biological Sciences*, 368, 20120429.

European Food Safety Authority (EFSA), Reich, H. & Triacchini, G.A. (2018) Occurrence of residues of fipronil and other acaricides in chicken eggs and poultry muscle/fat. *EFSA Journal*, 16, 5164.

FAO (Food and Agriculture Organization of the United Nations) (2012) *International Code of Conduct on the Distribution and Use of Pesticides. Guidelines on Prevention and Management of Pesticide Resistance.* 

http://www.fao.org/fileadmin/templates/agphome/documents/Pests\_Pesticides/Code/FAO\_RMG\_S ept\_12.pdf (latest accessed on January 27, 2019)

Fletcher, M.G. & Axtell, R.C. (1991) Susceptibilities of northern fowl mite, *Ornithonyssus sylviarum* (Acarina: Macronyssidae), and chicken mite, *Dermanyssus gallinae* (Acarina: Dermanyssidae), to selected acaricides. *Experimental and Applied Acarology*, 13, 137-142.

George, D.R., Finn, R.D., Graham, K.M., Mul, M.F., Maurer, V., Valiente Moro, C. & Sparagano, O.A.E. (2015) Should the poultry red mite *Dermanyssus gallinae* be of wider concern for veterinary and medical science? *Parasites & Vectors*, 8, 178.

Hubert, J., Erban, T., Kopecky, J., Sopko, B., Nesvorna, M., Lichovnikova, M., Schicht, S., Strube, C. & Sparagano, O. (2017) Comparison of microbiomes between red poultry mite populations (*Dermanyssus gallinae*): predominance of *Bartonella*-like bacteria. *Microbial Ecology*, 74, 947-960.

Ivey, M.C., Wayne Ivie, G., Devaney, G. & Beerwinkle, K.R. (1984) Residues of carbaryl and two of its metabolites in eggs of laying hens treated with Sevin® for Northern fowl mite control by dipping. *Poultry Science*, 63, 61-65.

Jonsson, N.N. & Hope, M. (2007) Progress in the epidemiology and diagnosis of amitraz resistance in the cattle tick *Boophilus microplus*. *Veterinary Parasitology*, 146, 193-198.

Kilpinen, O., Roepstorff, A., Permin A., Nørgaard-Nielsen, G., Lawson, L.G. & Simonsen, H.B. (2005) Influence of *Dermanyssus gallinae* and *Ascaridia galli* infections on behaviour and health of laying hens (*Gallus gallus domesticus*). *British Poultry Science*, 46, 26-34.

Kirst, H.A. (2010) The spinosyn family of insecticides: realizing the potential of natural products research. *The Journal of Antibiotics*, 63, 101-111.

Li, A.Y., Davey, R.B., Miller, R.J. & George J.H. (2004) Detection and characterization of amitraz resistance in the Southern cattle tick, *Boophilus microplus* (Acari: Ixodidae). *Journal of Medical Entomology*, 41, 193-200.

Marangi, M., Cafiero, M.A., Capelli, G., Camarda, A., Sparagano, O.A.E. & Giangaspero, A. (2009) Evaluation of the poultry red mite, *Dermanyssus gallinae* (Acari: Dermanyssidae) susceptibility to some acaricides in field populations from Italy. *Experimental and Applied Acarology*, 48, 11-18.

Marangi, M., Morelli, V., Pati, S., Camarda, A., Cafiero, M.A. & Giangaspero, A. (2012) Acaricide residues in laying hens naturally infested by red mite *Dermanyssus gallinae*. *PLoS One*, 7, e31795.

Mullens, B.A., Murillo, A.C., Zoller, H., Heckeroth, A.R., Jirjis, F. & Flochlay-Sigognault, A. (2017) Comparative in vitro evaluation of contact activity of fluralaner, spinosad, phoxim, propoxur, permethrin and deltamethrin against the northern fowl mite, *Ornithonyssus sylviarum*. *Parasites & Vectors*, 10, 358.

Mul, M., Van Niekerk, T., Chirico, J., Maurer, V., Kilpinen, O., Sparagano, O., Thind, B., Zoons, J., Moore, D., Bell, B., Gjevre, A.G. & Chauve, C. (2009) Control methods for *Dermanyssus gallinae* in systems for laying hens: results of an international seminar. *World's Poultry Science Journal*, 65, 589-599.

Navarrete-Dechent, C & Uribe, P. (2018) A case of gamasidosis caused by *Dermanyssus gallinae*, misdiagnosed as delusional parasitosis. *Clinical and Experimental Dermatology*, 8, 950.952.

Nordenfors, H., Höglund, J., Tauson, R. & Chirico J. (2001) Effect of permethrin impregnated plastic strips on *Dermanyssus gallinae* in loose-housing system for laying hens. *Veterinary Parasitology*, 102, 121-131.

Padula, G., Ponzinibbio, M.V., Picco, S. & Seoane, A. (2012) Assessment of the adverse effects of the acaricides amitraz: *in vitro* evaluation of genotoxicity. *Toxicology Mechanisms and Methods*, 22, 657-661.

Pugliese, N., Circella, E., Marino, M., De Virgilio, C., Cocciolo, G., Lozito, P., Cafiero, M.A. & Camarda A. (2018) Circulation dynamics of *Salmonella enterica* subsp. *enterica* ser. Gallinarum biovar Gallinarum in a poultry farm infested by *Dermanyssus gallinae*. *Medical and Veterinary Entomology*, in press.

R Core Team (2018) *R: a language and environment for statistical computing*. Vienna: R Foundation for Statistical Computing. https://www.R-project.org (latest accessed on February 25, 2019).

Raele, D.A., Galante, D., Pugliese, N., La Salandra, M., Lomuto, M. & Cafiero, M.A. (2018) First report of *Coxiella burnetii* and *Borrelia burgdorferi* sensu lato in poultry red mites, *Dermanyssus* 

gallinae (Mesostigmata, Acari), related to urban outbreaks of dermatitis in Italy. New Microbes and New Infections, 22, 103-109.

Schuetze, C.F. (2017) Tainted eggs prompt scare in Europe. *The New York Times*.

https://www.nytimes.com/2017/08/07/world/europe/eggs-belgium-germany-netherlands.html (latest accessed on January 27, 2019).

Sigognault-Flochlay, A., Thomas, E & Sparagano O. (2017) Poultry red mite (*Dermanyssus gallinae*) infestation: a broad impact parasitological disease that still remains a significant challenge for the egg-laying industry in Europe. *Parasites & Vectors*, 10, 357.

Sparagano, O.A.E., George, D.R., Harrington D.W.J. & Giangaspero A. (2014) Significance and control of the poultry red mite, *Dermanyssus gallinae*. *Annual Review of Entomology*, 59, 447-466. Sparagano, O., Pavlićević, A., Murano, T., Camarda, A., Sahibi, H., Kilpinen, O., Mul, M., van Emous, R., le Bouquin, S., Hoel, K. & Cafiero, M.A. (2009) Prevalence and key figures for the poultry red mite *Dermanyssus gallinae* infestations in poultry farm systems. *Experimental and Applied Acarology*, 48, 3-10.

Sparks, T.C. & Nauen, R. (2015) IRAC: mode of action classification and insecticide resistance management. *Pesticide Biochemistry and Physiology*, 121, 122-128.

Szerletics-Túri, M, Soós, K. & Végh, E. (2000) Determination of residues of pyrethroids and organophosphorous ectoparasiticides in foods of animal origin. *Acta Veterinaria Hungarica*, 48, 139-149.

Thind, B.B. & Muggleton J. (1998) A new bioassay method for the detection of resistance to pesticides in the stored product mite *Acarus siro* (Acari: Acaridae). *Experimental and Applied Acarology*, 22, 543-552.

Thomas, E., Zoller, H., Liebisch, G., Alves, L.F.A., Vettorato, L., Chiummo, R.M. & Sigognault-Flochlay, A. (2018) *In vitro* activity of fluralaner and other commonly used acaricides against *Dermanyssus gallinae* isolates from Europe and Brazil. *Parasites & Vectors*, 11, 361.

Tomley, F. M. & Sparagano, O. (2018) Spotlight on avian pathology: red mite, a serious emergent problem in layer hens. *Avian Pathology*, 47, 533-535.

Valiente Moro, C., Chauve, C. & Zenner, L. (2007) Experimental infection of *Salmonella* Enteritidis by the poultry red mite, *Dermanyssus gallinae. Veterinary Parasitology*, 146, 329-336. Varma, M.G.R. (1993) Ticks and mites (Acari). In: R.P. Lane & R.W. Crosskey (Eds). *Medical Insects and Arachnids* (pp. 597–658). Cambridge: University Press.

WHO Expert Committee on Vector Biology and Control (1992) *Vector resistance to pesticides:* fifteenth report of the WHO Expert Committee on Vector Biology and Control. Geneva: World Health Organization.

WHO (2009) Guidelines for efficacy testing of insecticides for indoor and outdoor ground-applied space spray applications. Geneva: World Health Organization.

Zeman, P. & Železný, J. (1985) The susceptibility of the poultry red mite, *Dermanyssus gallinae* (De Geer, 1778), to some acaricides under laboratory conditions. *Experimental and Applied Acarology*, 1, 17-22.

**Table 1.** Size of *Dermanyssus gallinae* populations analyzed by year.

|        | Analyzed mite |
|--------|---------------|
| Year   | populations   |
| 2008   | 6             |
| 2009   | 15            |
| 2010   | 24            |
| 2011   | 14//          |
| 2012 ( | 7             |
| 2013   | 6             |
| 2014   | 9             |
| 2015   | 5             |
|        |               |

**Table 2.** Percent efficacy of the acaricide drugs at field concentration by year.

|       | λ-     | cyhalothr | in     |        | Amitraz |        |        | Phoxim |        |
|-------|--------|-----------|--------|--------|---------|--------|--------|--------|--------|
| Year  | Lower  | Medi      | Upper  | Lower  | Medi    | Upper  | Lower  | Medi   | Upper  |
|       | limit* | an        | limit* | limit* | an      | limit* | limit* | an     | limit* |
|       |        |           |        |        | 100.0   |        |        |        |        |
| 2008  | 41.67  | 58.34     | 80.30  | 100.00 | 0       | 100.00 | 90.83  | 95.41  | 100.00 |
| 2009  | 43.33  | 68.35     | 87.50  | 76.67  | 90.00   | 100.00 | 63.33  | 80.00  | 100.00 |
| 2010  | 48.33  | 62.50     | 83.33  | 67.50  | 87.50   | 95.00  | 55.00  | 75.00  | 91.67  |
| 2011  | 53.33  | 62.84     | 86.67  | 51.67  | 67.92   | 91.84  | 53.33  | 77.50  | 100.00 |
| 2012  | 1.67   | 24.17     | 83.33  | 8.33   | 50.00   | 80.00  | 28.33  | 83.33  | 100.00 |
| 2013  | 3.33   | 40.00     | 61.67  | 26.67  | 64.59   | 91.67  | 20.83  | 76.67  | 100.00 |
| 2014  | 1.67   | 41.67     | 78.33  | 22.50  | 78.33   | 95.00  | 81.67  | 98.33  | 100.00 |
| 2015  | 15.46  | 43.57     | 60.46  | 53.34  | 76.67   | 100.00 | 3.89   | 45.00  | 76.67  |
| 2008- | 55.00  | 66.67     | 75.00  | 76.67  | 85.00   | 91.84  | 70.00  | 80.00  | 91.67  |
| 2011  | 33.00  | 00.07     | /3.00  | )/0.07 | 05.00   | 91.04  | 70.00  | 00.00  | 91.07  |
| 2012- | 22.22  | 40.00     | (0.02  | 25.00  | (2.0)   | 00.00  | (( (7  | 02.22  | 00.22  |
| 2015  | 23.33  | 40.00     | 60.83  | 35.00  | 62.96   | 80.00  | 66.67  | 83.33  | 98.33  |
| 2008- |        |           |        |        |         |        |        |        |        |
| 2015  | 48.33  | 58.33     | 68.33  | 71.25  | 80.83   | 88.33  | 75.00  | 80.35  | 91.67  |


<sup>\*</sup> Lower and upper limits are referred to the 95% confidence interval.

**Table 3.** Distribution of mite populations according to the efficacy of acaricides at field concentration (0.5 g/L  $\lambda$ -cyhalothrin, 0.5 g/ amitraz, 2 g/L phoxim).


|               |               | λ-c        | yhalo      | thrin      |                 |               | 4          | Amitr      | az         |                 |               |            | Phoxi      | m          |                 |
|---------------|---------------|------------|------------|------------|-----------------|---------------|------------|------------|------------|-----------------|---------------|------------|------------|------------|-----------------|
| Year          | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100<br>% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100<br>% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100<br>% |
| 2008          | 0.0           | 25.0       | 25.0       | 50.0       | 0.0             | 0.0           | 0.0        | 0.0        | 0.0        | 100.<br>0       | 0.0           | 0.0        | 16.7       | 0.0        | 83.3            |
| 2009          | 13.<br>3      | 6.7        | 20.0       | 26.7       | 33.3            | 0.0           | 0.0        | 6.7        | 26.7       | 66.7            | 0.0           | 6.7        | 13.        | 33.3       | 46.7            |
| 2010          | 4.5           | 18.2       | 27.3       | 22.7       | 27.3            | 0.0           | 4.6        | 13.6       | 13.6       | 68.2            | 8.3           | 0.0        | 25.<br>0   | 25.0       | 41. 7           |
| 2011          | 0.0           | 7.1        | 42.9       | 21.4       | 28.6            | 0.0           | 14.3       | 21.4       | 28.6       | 35.7            | 7.1           | 0.0        | 28.6       | 28.6       | 35.7            |
| 2012          | 50.<br>0      | 33.3       | 0.0        | 0.0        | 16.7            | 14.<br>3      | 28.6       | 42.9       | 14.3       | 0.0             | 0.0           | 14.3       | 0.0        | 28.6       | 57.1            |
| 2013          | 16.<br>7      | 33.3       | 33.3       | 16.7       | 0.0             | 0.0           | 33.3       | 0.0        | 33.3       | 33.3            | 16)           | 0.0        | 33.3       | 0.0        | 50.0            |
| 2014          | 33.<br>3      | 11.1       | 11.1       | 33.3       | 11.1            | 0.0           | 22.<br>2   | 0.0        | 33.3       | 44.4            | 0.0           | 0.0        | 0.0        | 11.<br>1   | 88. 9           |
| 2015          | 0.0           | 25.0       | 50.0       | 25.0       | 0.0             | 0.0           | 20.<br>0   | 0.0        | 60.0       | 20.0            | 20.<br>0      | 20.0       | 20.0       | 20.<br>0   | 20.0            |
| 2008-<br>2011 | 5.5           | 12.7       | 29.1       | 25.5       | 27.3            | 0.0           | 5.5        | 12.7       | 20.0       | 61.8            | 5.1           | 1.7        | 22.0       | 25.4       | 45.7            |
| 2012-<br>2015 | 28.<br>0      | 24.0       | 20.0       | 20.0       | 8.0             | 3.7           | 25.9       | 11.1       | 33.3       | 25.9            | 7.4           | 7.4        | 11.1       | 14.8       | 59.3            |
| 2008-<br>2015 | 12.<br>5      | 16.3       | 26.3       | 23.8       | 21.3            | 1,2           | 12.2       | 12.2       | 24.4       | 50.0            | 5.8           | 3.5        | 18.6       | 22.1       | 50.0            |

### Figure legends

**Figure 1.** Trends of the median percent efficacy of  $\lambda$ -cyhalothrin (white bars), amitraz (dotted bars), phoxim (grey bars) at the field concentration (0.5 g/L  $\lambda$ -cyhalothrin, 0.5 g/L amitraz, 2 g/L phoxim) by year.



**Figure S1.** Mites populations per efficacy class at field concentration (0.5 g/L  $\lambda$ -cyhalothrin, 0.5 g/L amitraz, 2 g/L phoxim). AM: amitraz; LC:  $\lambda$ -cyhalothrin; PH: phoxim.



**Figure S2.** Mites populations per efficacy class at field concentration (0.5 g/L  $\lambda$ -cyhalothrin, 0.5 g/L amitraz, 2 g/L phoxim) in the four-year period 2008-2011 (a) and 2012-2015 (b). AM: amitraz; LC:  $\lambda$ -cyhalothrin; PH: phoxim.

Supplementary table S1. Percent efficacy of  $\lambda$  -cyhalothrin at different concentrations.

|          |                         | halo<br>4X <sup>1</sup> | thrin        | λ -cy                   | halot<br>2X <sup>2</sup> | hrin         | λ -cyl                  | halot<br>1 X <sup>3</sup> | hrin         | λ -cyl                  | nalot<br>.5X <sup>4</sup> | hrin        | λ -cyl                  | naloth<br>25X <sup>5</sup> | nrin                    |
|----------|-------------------------|-------------------------|--------------|-------------------------|--------------------------|--------------|-------------------------|---------------------------|--------------|-------------------------|---------------------------|-------------|-------------------------|----------------------------|-------------------------|
| Yea<br>r | Low<br>er<br>limit<br>* | M<br>edi<br>an          | Upper limit* | Low<br>er<br>limit<br>* | M<br>edi<br>an           | Upper limit* | Low<br>er<br>limit<br>* | M<br>edi<br>an            | Upper limit* | Low<br>er<br>limit<br>* | M<br>edi<br>an            | r<br>limit* | Low<br>er<br>limit<br>* | M<br>edi<br>an             | Upp<br>er<br>limit<br>* |
| 200      | 55.0                    | 58.                     | 61.67        | 51.6                    | <b>59.</b>               | 68.34        | 41.6                    | 58.                       | 80 30        | 38.3                    | 54.                       | 71.66       | 23.3                    | 39.                        | 58.3                    |
| 8        | 0                       | 34                      | 01.07        | 7                       | <b>17</b>                | 00.54        | 7                       | 34                        | 80.50        | 3                       | <b>17</b>                 | /1.00       | 4                       | <b>17</b>                  | 4                       |
| 200      | 51.6                    | <b>73.</b>              | 85.00        | 48.3                    | <b>66.</b>               | 93.33        | 43.3                    | <b>68.</b>                | 87.50        | 46.6                    | <b>58.</b>                | 83.33       | 8.33                    | <b>60.</b>                 | 81.6                    |
| 9        | 7                       | <b>35</b>               | 83.00        | 3                       | <b>67</b>                | 75.55        | 3                       | 35                        | 07.30        | 7                       | 33                        | 03.33       | 0.33                    | 00                         | 7                       |

| 201<br>0                          | 48.3      | 70.<br>84 | 88.33 | 50.0      | 65.<br>84 | 91.67 | 48.3      | 62.<br>50     | 83.33 | 33.3      | 52.<br>50 | 68.33 | 26.6<br>7 | 47.<br>50 | 80.0      |
|-----------------------------------|-----------|-----------|-------|-----------|-----------|-------|-----------|---------------|-------|-----------|-----------|-------|-----------|-----------|-----------|
| 201<br>1                          | 43.3      | 75.<br>00 | 86.67 | 40.0<br>0 | 74.<br>17 | 88.33 | 53.3<br>3 | 62.<br>84     | 86.67 | 37.5<br>0 | 58.<br>33 | 95.00 | 18.3<br>5 | 47.<br>92 | 85.0<br>0 |
| 201<br>2                          | 3.33      | 31.<br>67 | 88.33 | 8.33      | 40.<br>00 | 85.00 | 1.67      | 24.<br>17     | 83.33 | 11.6<br>7 | 24.<br>17 | 55.00 | 5.00      | 15.<br>84 | 23.3      |
| 201<br>3                          | 23.3      | 50.<br>00 | 65.00 | 10.0<br>0 | 36.<br>67 | 77.50 | 3.33      | <b>40. 00</b> | 61.67 | 0.00      | 31.<br>67 | 61.67 | 5.00      | 25.<br>00 | 55.8<br>3 |
| 201<br>4                          | 3.33      | 63.<br>33 | 91.67 | 5.00      | 58.<br>33 | 90.00 | 1.67      | 41.<br>67     | 78.33 | 26.6<br>7 | 50.<br>00 | 83.33 | 10.0      | 48.<br>33 | 65.0      |
| 201<br>5                          | 45.0<br>0 | 61.<br>67 | 88.14 | 25.8<br>3 | 50.<br>42 | 64.16 | 15.4<br>6 | 43.<br>57     | 60.46 | 0.00      | 18.<br>34 | 26.95 | 11.6      | 20.<br>84 | 31.6      |
| 200<br>8-                         | 61.6      | 70.<br>00 | 78.33 | 61.6      | 66.<br>67 | 76.67 | 55.0<br>0 | 66.<br>67     | 75.00 | 48.3      |           | 68.33 | 37.5      | 46.<br>67 | 60.0      |
| 201                               | 7         |           |       | 3         | O7        |       | U         | 07            |       | 3         | 00        | > 0   | )0        | O1        | U         |
| 201<br>1<br>201<br>2-<br>201<br>5 |           | 45.<br>00 | 65.00 | 35.0      |           | 63.33 | 23.3      |               | 60.83 | 18.3      |           | 50.00 | 11.6<br>7 | 20.<br>00 | 30.0      |

<sup>&</sup>lt;sup>1</sup> 4X: four times the field concentration; <sup>2</sup> 2X: two times the field concentration; <sup>3</sup>: 1X: field concentration; <sup>4</sup> 0.5X: half the field concentration; <sup>5</sup> 0.25X: one quarter the field concentration. \*Upper and lower limits are referred to the 0.95 confidence interval.

## Supplementary table S2. Percent efficacy of amitraz at different concentrations.

|          | Ami   | itraz     | $4X^1$     | Am    | itraz          | $2X^2$ | Am    | itraz          | $1X^3$ | Amit  | traz (    | $0.5X^4$ | Amit            | raz 0.    | $.25X^5$ |
|----------|-------|-----------|------------|-------|----------------|--------|-------|----------------|--------|-------|-----------|----------|-----------------|-----------|----------|
| Yea      | Lowe  | Me        | Uppe       | Lowe  | Me             | Uppe   | Lowe  | Me             | Uppe   | Lowe  | Me        | Uppe     | Lowe            | Me        | Uppe     |
| r        | limit | dia       | limit      | limit | dia            | limit  | limit | dia            | limit  | limit | dia       | limit    | r<br>limit<br>* | dia       | limit    |
|          | *     |           | *          | *     | 11             | *      | *     | 11             | *      | *     | 11        | *        | *               | 11        | *        |
| 200      | 98.33 | 99.<br>16 | 100.0      | 100.0 | 10<br>0.0<br>0 | 100.0  | 100.0 | 10<br>0.0<br>0 | 100.0  | 93.33 | 96.<br>67 | 100.0    | 83.33           | 89.<br>17 | 100.0    |
| 200      |       |           | 100.0<br>0 |       |                |        |       |                |        |       |           |          |                 |           |          |
| 201<br>0 | 86.67 | 96.<br>25 | 100.0      | 73.33 | 95.<br>00      | 96.67  | 87.50 | 67.<br>50      | 95.00  | 56.67 | 69.<br>38 | 83.75    | 46.67           | 65.<br>00 | 80.00    |
| 201<br>1 | 76.67 | 91.<br>67 | 100.0      | 35.00 | 88.<br>33      | 95.92  | 51.67 | 67.<br>92      | 91.84  | 31.67 | 55.<br>84 | 81.63    | 28.33           | 48.<br>33 | 70.00    |
| 201<br>2 | 16.97 | 33.<br>33 | 91.67      | 5.00  | 31.<br>67      | 90.00  | 8.33  | 50.<br>00      | 80.00  | 0.00  | 25.<br>00 | 61.67    | 0.00            | 20.<br>00 | 43.33    |
| 201      | 40.00 | 92.       | 98.33      | 28.33 | 80.            | 96.67  | 26.67 | <b>64.</b>     | 91.67  | 18.33 | 47.       | 80.00    | 10.00           | 28.       | 75.00    |

| 3                     |       | <b>50</b>      |       |       | 00        |       |       | 59        |       |       | 09        |       |       | 33                               |       |
|-----------------------|-------|----------------|-------|-------|-----------|-------|-------|-----------|-------|-------|-----------|-------|-------|----------------------------------|-------|
| 201<br>4              |       |                |       | 28.33 | 85.<br>00 | 95.00 | 22.50 | 78.<br>33 | 95.00 | 8.33  | 70.<br>00 | 93.33 | 16.67 | <ul><li>53.</li><li>33</li></ul> | 95.00 |
| 201                   | 100.0 | 10<br>0.0<br>0 | 100.0 | 80.00 | 90.<br>00 | 100.0 | 53.34 | 76.<br>67 | 100.0 | 13.34 | 56.<br>67 | 83.34 | 0.00  | 45.<br>00                        | 70.00 |
| 200<br>8-<br>201<br>1 | 95.00 | 98.<br>33      | 98.33 | 88.33 | 95.<br>00 | 96.67 | 76.67 | 85.<br>00 | 91.84 | 60.00 | 75.<br>00 | 82.50 | 58.75 | 69.<br>17                        | 73,33 |
| 201<br>2-<br>201<br>5 | 43.33 | 71.<br>67      | 98.33 | 33.33 | 76.<br>67 | 90.00 | 35.00 | 62.<br>96 | 80.00 | 20.00 | 33.<br>33 | 62.96 | 28.33 | 56.<br>02                        | 70.00 |
| 200<br>8-<br>201<br>5 | 91.67 | 96.<br>67      | 98.33 | 85.00 | 90.<br>00 | 95.00 | 71.25 | 80.<br>83 | 88.33 | 56.67 | 66.<br>67 | 75,00 | 48.33 | 60.<br>00                        | 70.00 |

<sup>&</sup>lt;sup>1</sup> 4X: four times the field concentration; <sup>2</sup> 2X: two times the field concentration; <sup>3</sup>: 1X: field concentration; <sup>4</sup> 0.5X: half the field concentration; <sup>5</sup> 0.25X: one quarter the field concentration. \*Upper and lower limits are referred to the 0.95 confidence interval.

# Supplementary table S3. Percent efficacy of phoxim at different concentrations.

|          | Pho                     | xim            | $4X^1$                  | Pho                     | xim            | $2X^2$                  | Pho                     | xim        | $1X^3$     | Phox       | im 0       | $.5X^4$    | Phox       | im 0.                            | 25X <sup>5</sup>        |
|----------|-------------------------|----------------|-------------------------|-------------------------|----------------|-------------------------|-------------------------|------------|------------|------------|------------|------------|------------|----------------------------------|-------------------------|
| Yea<br>r | Lowe<br>r<br>limit<br>* | Me<br>dia<br>n | Uppe<br>r<br>limit<br>* | Lowe<br>r<br>limit<br>* | Me<br>dia<br>n | Uppe<br>r<br>limit<br>* | Lowe<br>r<br>limit<br>* | dia<br>n   | limit<br>* | limit<br>* | dia<br>n   | limit<br>* | limit<br>* | Me<br>dia<br>n                   | Uppe<br>r<br>limit<br>* |
| 200<br>8 | 76.67                   | 88.<br>34      | 95.84                   |                         | U/             | 88.33                   | 90.83                   | 41         | U          |            | JT         | 100.0      | 51.67      | 70.<br>41                        | 86.67                   |
| 200<br>9 | 70.00                   | 90.<br>00      | 98.33                   | 71.67                   |                |                         | 63.33                   | VV         | U          | 60.00      | U/         | 92.50      |            | 55                               | 80.00                   |
| 201<br>0 | 63.33                   | 86.<br>67      | 96.67                   | 61.67                   | 80.<br>84      | 93.33                   | 55.00                   | 75.<br>00  | 91.67      | 48.33      | 0,         |            |            | _,                               | 75.00                   |
| 201      | 73.33                   | 86.<br>67      | 0                       | 53.33                   | JT             | 100.0<br>0              |                         |            |            | 46.67      |            | 95.00      | 30.00      | 58.<br>33                        | 97.96                   |
| 201      | 76.67                   | 95.<br>00      | 0                       |                         | U/             | 100.0<br>0              |                         | 55         | U          | 10.00      | 55         | 88.33      |            | <ul><li>51.</li><li>67</li></ul> | 08.33                   |
| 201      | 35.00                   | 92.<br>50      | U                       | 35.83                   | 33             | 100.0                   | 20.83                   | 76.<br>67  | 100.0      | 21.67      | 64.<br>17  | 90.00      | 15.00      | 36.<br>25                        | 90.00                   |
| 201<br>4 | 98.33                   | 10<br>0.0<br>0 | 100.0                   | 96.67                   | 10<br>0.0<br>0 | 100.0                   | 81.67                   | 98.<br>33  | 100.0      | 70.00      | 91.<br>67  | 100.0      | 61.67      | 90.<br>00                        | 100.0                   |
| 201<br>5 | 65.18                   | 73.<br>33      | 98.33                   | 36.94                   | 65.<br>00      | 90.00                   | 3.89                    | 45.<br>00  | 76.67      | 0.00       | 35.<br>00  | 66.67      | 0.00       | 31.<br>67                        | 60.84                   |
| 200      | 80.00                   | 96.            | 100.0                   | 75.00                   | 96.            | 100.0                   | 70.00                   | <b>80.</b> | 91.67      | 60.00      | <b>71.</b> | 80.00      | 58.33      | <b>65.</b>                       | 75.00                   |

| 8-        |       | <b>67</b> | 0       |       | <b>67</b> | 0       |       | 00        |       |       | <b>67</b> |       |       | 00         |       |
|-----------|-------|-----------|---------|-------|-----------|---------|-------|-----------|-------|-------|-----------|-------|-------|------------|-------|
| 201       |       |           |         |       |           |         |       |           |       |       |           |       |       |            |       |
| 1         |       |           |         |       |           |         |       |           |       |       |           |       |       |            |       |
| 201       |       | 04        | 100.0   |       | 04        | 100.0   |       | 02        |       |       | 75        |       |       | <i>55</i>  |       |
| 2-<br>201 | 80.00 | 90.<br>67 | 0.01    | 75.00 | 90.<br>67 | 0.01    | 66.67 | os.<br>33 | 98.33 | 43.33 | /5.<br>00 | 90.00 | 31.67 | 55.<br>00  | 78.33 |
| 5         |       | 07        | O       |       | 07        | O       |       |           |       |       | 00        |       |       | 00         |       |
| 200       |       |           |         |       |           |         |       |           |       |       |           |       |       |            |       |
| 8-        | 81.67 | 90.       | 95.00   | 80.00 | 86.       | 93.06   | 75.00 | 80.       | 91.67 | 61.67 | 72.       | 80.00 | 56.67 | <b>62.</b> | 72.50 |
| 201       |       | 00        | , , , , |       | 67        | , , , , |       | 35        | , _,, |       | 50        |       |       | 91         |       |
| <u> </u>  |       |           |         |       |           |         |       |           |       |       |           |       |       | 1          |       |

<sup>&</sup>lt;sup>1</sup> 4X: four times the field concentration; <sup>2</sup> 2X: two times the field concentration; <sup>3</sup>: 1X: field concentration; <sup>4</sup> 0.5X: half the field concentration; <sup>5</sup> 0.25X: one quarter the field concentration. \*Upper and lower limits are referred to the 0.95 confidence interval.

**Table S4.** Percent of mite populations falling within the five efficacy classes of the acaricide drugs at four times the field concentration.

|       |               | λ-с        | yhalot     | hrin       |             |               | A          | mitra      | Z          | >           |               | P          | hoxim      | 1          |                 |
|-------|---------------|------------|------------|------------|-------------|---------------|------------|------------|------------|-------------|---------------|------------|------------|------------|-----------------|
| Year  | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100<br>% |
| 2008  | 0.00          | 0.00       | 75.0<br>0% | 25.0<br>0% | 0.00        | 0.00          | 0.00       | 0.00       | 0.00       | 100.0       | 0.0           | 0.00       | 0.00       | 16.6<br>7% | 83.3            |
| 2009  | 0.00          | 13.3<br>3% | 20.0<br>0% | 33.3<br>3% | 33.33       | 0.00          | 0.00       | 0.00       | 0.00       | 100.0<br>0% | 6.6<br>7%     | 0.00       | 6.67       | 13.3<br>3% | 73.3<br>3%      |
| 2010  | 9.09          | 0.00       | 22.7       | 36.3       | 31.82       | 0.00          | 0.00       | 0.00       | 13.6       | 86.36       | 0.0           | 4.17       | 20.8       | 16.6       | 58.3            |
| 2011  | %<br>14.2     | %<br>0.00  | 3%<br>14.2 | 6%<br>35.7 | %<br>35.71  | %<br>0.00     | %<br>7.69  | %<br>7.69  | 4%<br>23.0 | %<br>61.54  | 0%<br>0.0     | %<br>0.00  | 3%<br>14.2 | 7%<br>21.4 | 3%<br>64.2      |
|       | 9%<br>33.3    | %<br>33.3  | 9%<br>16.6 | 1%<br>0.00 | %<br>16.67  | %<br>14.2     | %<br>42.8  | %<br>28.5  | 8%<br>0.00 | %<br>14.29  | 0%<br>0.0     | %<br>0.00  | 9%<br>0.00 | 3%<br>14.2 | 9%<br>85.7      |
| 2012  | 3%            | 3%         | 7%         | %          | %           | 9%            | 6%         | 7%         | %          | %           | 0%            | %          | %          | 9%         | 1%              |
| 2013  | 0.00          | 33.3<br>3% | 33.3<br>3% | 33.3<br>3% | 0.00<br>%   | 0.00          | 16.6<br>7% | 16.6<br>7% | 0.00<br>%  | 66.67       | 0.0<br>0%     | 16.6<br>7% | 0.00       | 16.6<br>7% | 66.6<br>7%      |
| 2014  | 22.2<br>2%    | 11.1       | 11.1<br>1% | 22.2<br>2% | 33.33       | 0.00          | 11.1<br>1% | 11.1<br>1% | 33.3<br>3% | 44.44<br>%  | 0.0<br>0%     | 0.00       | 0.00       | 11.1<br>1% | 88.8<br>9%      |
| 2015  | 0.00          | 25.0<br>0% | 25.0<br>0% | 50.0<br>0% | 0.00        | 0.00          | 0.00       | 0.00       | 20.0       | 80.00       | 0.0<br>0%     | 0.00       | 40.0<br>0% | 40.0<br>0% | 20.0<br>0%      |
| 2008- | 7.27          | 3.64       | 23.6       | 34.5       | 30.91       | 0.00          | 1.85       | 1.85       | 11.1       | 85.19       | 1.6           | 1.69       | 13.5       | 16.9       | 66.1            |
| 2011  | %             | %          | <b>4%</b>  | 5%         | %           | %             | %          | %          | 1%         | %           | 9%            | %          | 6%         | 5%         | 0%              |
| 2012- | 16.0          | 24.0       | 20.0       | 24.0       | 16.00       | 3.70          | 18.5       | 14.8       | 14.8       | 48.15       | 0.0           | 3.70       | 7.41       | 18.5       | 70.3            |
| 2015  | 0%            | 0%         | 0%         | 0%         | %           | %             | 2%         | 1%         | 1%         | %           | 0%            | %          | %          | 2%         | 7%              |
| 2008- | 10.0          | 10.0       | 22.5       | 31.2       | 26.25       | 1.23          | 7.41       | 6.17       | 12.3       | 72.84       | 1.1           | 2.33       | 11.6       | 17.4       | 67.4            |
| 2015  | 0%            | 0%         | 0%         | 5%         | %           | %             | %          | %          | 5%         | %           | 6%            | %          | 3%         | 4%         | 4%              |

**Table S5.** Percent of mite populations falling within the five efficacy classes of the acaricide drugs at two times the field concentration.

|       |               | λ-c        | yhalot     | hrin       |             |                | A          | mitra      | Z          |             |               | P          | hoxim      | l          |                 |
|-------|---------------|------------|------------|------------|-------------|----------------|------------|------------|------------|-------------|---------------|------------|------------|------------|-----------------|
| Year  | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>%  | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100<br>% |
| 2008  | 0.00          | 0.00       | 50.0<br>0% | 50.0<br>0% | 0.00%       | 0.0            | 0.00       | 0.00       | 0.00       | 100.0<br>0% | 0.0           | 0.00       | 0.00       | 50.0       | 50.0            |
| 2009  | 0.00          | 13.3<br>3% | 26.6<br>7% | 20.0       | 40.00       | 0.0<br>0%      | 0.00       | 0.00       | 6.67       | 93.33       | 6.6<br>7%     | 0.00       | 6.67       | 20.0<br>0% | 66.6<br>7%      |
| 2010  | 4.55          | 13.6<br>4% | 9.09       | 40.9<br>1% | 31.82       | 0.0<br>0%      | 0.00       | 9.09       | 22.7<br>3% | 68.18       | 4.1<br>7%     | 4.17       | 12.5       | 29.1<br>7% | 50.0            |
| 2011  | 0.00          | 21.4       | 14.2<br>9% | 21.4       | 42.86       | 7.6<br>9%      | 15.3<br>8% | 0.00       | 23.0<br>8% | 53.85       | 0.0           | 7.14       | 14.2<br>9% | 28.5<br>7% | 50.0<br>0%      |
| 2012  | 33.3<br>3%    | 16.6<br>7% | 33.3<br>3% | 0.00       | 16.67<br>%  | 14.<br>29<br>% | 71.4<br>3% | 0.00       | 0.00       | 14.29       | 0.0           | 0.00       | 0.00       | 14.2<br>9% | 85.7<br>1%      |
| 2013  | 16.6<br>7%    | 33.3<br>3% | 33.3<br>3% | 16.6<br>7% | 0.00%       | 0.0<br>0%      | 16.6<br>7% | 16.6<br>7% | 16.6<br>7% | 50.00       | 0.0<br>0%     | 16.6<br>7% | 16.6<br>7% | 16.6<br>7% | 50.0<br>0%      |
| 2014  | 22.2<br>2%    | 11.1<br>1% | 22.2<br>2% | 11.1<br>1% | 33.33       | 11.<br>11<br>% | 11.1<br>1% | 11.1<br>1% | 11.1<br>1% | 55.56<br>%  | 0.0<br>0%     | 0.00       | 0.00       | 0.00       | 100.<br>00%     |
| 2015  | 0.00          | 50.0<br>0% | 0.00       | 50.0<br>0% | 0.00%       | 0.0<br>0%      | 0.00       | 20.0<br>0% | 0.00       | 80.00       | 0.0<br>0%     | 0.00       | 40.0<br>0% | 40.0<br>0% | 20.0<br>0%      |
| 2008- | 1.82          | 14.5       | 18.1       | 30.9       | 34.55       | 1.8            | 3.70       | 3.70       | 16.6       | 74.07       | 3.3           | 3.39       | 10.1       | 28.8       | 54.2            |
| 2011  | %             | 5%         | 8%         | 1%         | %           | 5%             | %          | %          | 7%         | %           | 9%            | %          | <b>7%</b>  | 1%         | 4%              |
| 2012- | 20.0          | 24.0       | 24.0       | 16.0       | 16.00       | 7.4            | 25.9       | 11.1       | 7.41       | 48.15       | 0.0           | 3.70       | 11.1       | 14.8       | 70.3            |
| 2015  | 0%            | 0%         | 0%         | 0%         | 0/0         | 1%             | 3%         | 1%         | %          | %           | 0%            | %          | 1%         | 1%         | 7%              |
| 2008- | 7.50          | 17.5       | 20.0       | 26.2       | 28.75       | 3.7            | 11.1       | 6.17       | 13.5       | 65.43       | 2.3           | 3.49       | 10.4       | 24.4       | 59.3            |
| 2015  | %             | 0%         | 0%         | 5%         | %           | 0%             | 1%         | %          | 8%         | %           | 3%            | %          | 7%         | 2%         | 0%              |

**Table S6.** Percent of mite populations falling within the five efficacy classes of the acaricide drugs at half the field concentration.

|      |               | λ-c        | yhalot     | hrin       |             |               | A          | Amitra     | Z          |             |               | F          | Phoxin     | 1          |                 |
|------|---------------|------------|------------|------------|-------------|---------------|------------|------------|------------|-------------|---------------|------------|------------|------------|-----------------|
| Year | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100<br>% |
| 2008 | 0.00          | 50.0       | 0.00       | 50.0       | 0.00        | 0.00          | 0.00       | 0.00       | 25.0       | 75.00       | 0.00          | 0.00       | 16.6       | 16.6       | 66.6            |
| 2000 | //%           | 0%         | %          | 0%         | %           | %             | %          | %          | 0%         | %           | %             | %          | 7%         | <b>7%</b>  | 7%              |
| 2009 | 13.3          | 0.00       | 40.0       | 20.0       | 26.67       | 0.00          | 6.67       | 20.0       | 26.6       | 46.67       | 6.67          | 0.00       | 20.0       | 33.3       | 40.0            |
| 2009 | 3%            | %          | 0%         | 0%         | %           | %             | %          | 0%         | 7%         | %           | %             | %          | 0%         | 3%         | 0%              |
| 2010 | 4.55          | 27.2       | 31.8       | 18.1       | 18.18       | 0.00          | 4.55       | 36.3       | 22.7       | 36.36       | 8.33          | 4.17       | 29.1       | 29.1       | 29.1            |
| 2010 | %             | 7%         | 2%         | 8%         | %           | %             | %          | 6%         | 3%         | %           | %             | %          | 7%         | 7%         | 7%              |
| 2011 | 7.14          | 14.2       | 28.5       | 14.2       | 35.71       | 7.14          | 21.4       | 28.5       | 21.4       | 21.43       | 7.14          | 7.14       | 35.7       | 28.5       | 21.4            |
| 2011 | %             | 9%         | <b>7%</b>  | 9%         | %           | %             | 3%         | <b>7%</b>  | 3%         | %           | %             | %          | 1%         | 7%         | 3%              |
| 2012 | 50.0          | 33.3       | 16.6       | 0.00       | 0.00        | 42.8          | 28.5       | 14.2       | 14.2       | 0.00        | 14.2          | 14.2       | 14.2       | 14.2       | 42.8            |
| 2012 | 0%            | 3%         | 7%         | %          | %           | 6%            | 7%         | 9%         | 9%         | %           | 9%            | 9%         | 9%         | 9%         | 6%              |
| 2013 | 50.0          | 0.00       | 33.3       | 16.6       | 0.00        | 16.6          | 33.3       | 16.6       | 33.3       | 0.00        | 0.00          | 33.3       | 16.6       | 0.00       | 50.0            |

|       | 0%   | %    | 3%   | 7%   | %     | 7%   | 3%   | <b>7%</b> | 3%        | %     | %    | 3%   | 7%   | %    | 0%   |
|-------|------|------|------|------|-------|------|------|-----------|-----------|-------|------|------|------|------|------|
| 2014  | 11.1 | 33.3 | 33.3 | 0.00 | 22.22 | 22.2 | 11.1 | 11.1      | 22.2      | 33.33 | 0.00 | 0.00 | 0.00 | 33.3 | 66.6 |
| 2014  | 1%   | 3%   | 3%   | %    | %     | 2%   | 1%   | 1%        | 2%        | %     | %    | %    | %    | 3%   | 7%   |
| 2015  | 50.0 | 25.0 | 25.0 | 0.00 | 0.00  | 0.00 | 20.0 | 40.0      | 20.0      | 20.00 | 20.0 | 40.0 | 0.00 | 20.0 | 20.0 |
| 2013  | 0%   | 0%   | 0%   | %    | %     | %    | 0%   | 0%        | 0%        | %     | 0%   | 0%   | %    | 0%   | 0%   |
| 2008- | 7.27 | 18.1 | 30.9 | 20.0 | 23.64 | 1.82 | 9.09 | 27.2      | 23.6      | 38.18 | 6.78 | 3.39 | 27.1 | 28.8 | 33.9 |
| 2011  | %    | 8%   | 1%   | 0%   | %     | %    | %    | <b>7%</b> | 4%        | %     | %    | %    | 2%   | 1%   | 0%   |
| 2012- | 36.0 | 24.0 | 28.0 | 4.00 | 8.00  | 22.2 | 22.2 | 18.5      | 22.2      | 14.81 | 7.41 | 18.5 | 7.41 | 18.5 | 48.1 |
| 2015  | 0%   | 0%   | 0%   | %    | %     | 2%   | 2%   | 2%        | 2%        | %     | %    | 2%   | %    | 2%   | 5%   |
| 2008- | 16.2 | 20.0 | 30.0 | 15.0 | 18.75 | 8.54 | 13.4 | 24.3      |           | 30.49 | 6.98 | 8.14 | 20.9 | 25.5 | 38.3 |
| 2015  | 5%   | 0%   | 0%   | 0%   | %     | %    | 1%   | 9%        | <b>7%</b> | %     | %    | %    | 3%   | 8%   | 7%   |

**Table S7.** Percent of mite populations falling within the five efficacy classes of the acaricide drugs at one quarter the field concentration.

|           | λ-cyhalothrin |            |            |            |             |               | Amitraz    |            |            | F           |               |            |            |            |                 |
|-----------|---------------|------------|------------|------------|-------------|---------------|------------|------------|------------|-------------|---------------|------------|------------|------------|-----------------|
| Year      | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100% | 0-<br>20<br>% | 21-<br>40% | 41-<br>60% | 61-<br>80% | 81-<br>100<br>% |
| 2008      | 25.0          | 25.0       | 50.0       | 0.00       | 0.00        | 0.00          | 0.00       | 0.00       | 25.0       | 75.00       | 0.00          | 0.00       | 33.3       | 50.0       | 16.6            |
|           | 0%            | 0%         | 0%         | %<br>20.0  | %           | %             | %          | %<br>2000  | 0%         | %<br>40.00  | %             | %          | 3%         | 0%         | 7%              |
| 2009      | 26.6<br>7%    | 6.67       | 20.0       | 20.0       | 26.67       | 0.00          | 6.67       | 20.0       | 33.3<br>3% | 40.00       | 6.67          | 0.00       | 13.3<br>3% | 60.0<br>0% | 20.0<br>0%      |
| • • • • • | 13.6          | 22.7       | 31.8       | 13.6       | 18.18       | 9.09          | 9.09       | 31.8       | 36.3       | 13.64       | 9.09          | 18.1       | 27.2       | 27.2       | 18.1            |
| 2010      | 4%            | 3%         | 2%         | 4%         | %           | %             | %          | 2%         | 6%         | %           | %             | 8%         | 7%         | 7%         | 8%              |
| 2011      | 21.4          | 21.4       | 21.4       | 14.2       | 21.43       | 7.69          | 38.4       | 15.3       | 38.4       | 0.00        | 14.2          | 21.4       | 21.4       | 14.2       | 28.5            |
| 2011      | 3%            | 3%         | 3%         | 9%         | %           | %             | 6%         | 8%         | 6%         | %           | 9%            | 3%         | 3%         | 9%         | 7%              |
| 2012      | 66.6          | 33.3       | 0.00       | 0.00       | 0.00        | 57.1          | 28.5       | 14.2       | 0.00       | 0.00        | 28.5          | 0.00       | 57.1       | 14.2       | 0.00            |
| 2012      | 7%            | 3%         | %          | %          | %           | 4%            | 7%         | 9%         | %          | %           | 7%            | %          | 4%         | 9%         | %               |
| 2013      | 50.0          | 33.3       |            | 0.00       | 0.00        | 33.3          | 33.3       | 0.00       | 33.3       | 0.00        | 33.3          | 16.6       | 16.6       | 16.6       | 16.6            |
| 2013      | 0%            | 3%         | 7%         | %          | > %         | 3%            | 3%         | %          | 3%         | %           | 3%            | <b>7%</b>  | 7%         | 7%         | 7%              |
| 2014      | 44.4          | 0.00       | 33.3       | 11.1       | 11.11       | 22.2          | 0.00       | 33.3       | 11.1       | 33.33       | 0.00          | 0.00       | 11.1       | 33.3       | 55.5            |
| 2011      | 4%            | %          | 3%         | 1%         | %           | 2%            | %          | 3%         | 1%         | %           | %             | %          | 1%         | 3%         | 6%              |
| 2015      | 50.0          | 50.0       | 0.00       | 0.00       | 0.00        | 40.0          | 0.00       | 20.0       | 20.0       | 20.00       | 40.0          | 40.0       | 0.00       | 0.00       | 20.0            |
| 2013      | 0%            | 0%         | %          | %          | %           | 0%            | %          | 0%         | 0%         | %           | 0%            | 0%         | %          | %          | 0%              |
| 2008-     | 20.0          | 18.1       | 27.2       | 14.5       | 20.00       | 5.56          | 14.8       | 22.2       | 35.1       | 22.22       | 8.77          | 12.2       | 22.8       | 35.0       | 21.0            |
| 2011      | 0%            | 8%         | 7%         | 5%         | %           | %             | 1%         | 2%         | 9%         | %           | %             | 8%         | 1%         | 9%         | 5%              |
| 2012-     | 52.0          | 24.0       | 16.0       | 4.00       | 4.00        | 37.0          | 14.8       | 18.5       | 14.8       | 14.81       | 22.2          | 11.1       | 22.2       | 18.5       | 25.9            |
| 2015      | 0%            | 0%         | 0%         | %          | %           | 4%            | 1%         | 2%         | 1%         | %           | 2%            | 1%         | 2%         | 2%         | 3%              |
| 2008-     | 30.0          | 20.0       | 23.7       | 11.2       | 15.00       | 16.0          | 14.8       | 20.9       | 28.4       | 19.75       | 13.1          | 11.9       | 22.6       | 29.7       | 22.6            |
| 2015      | 0%            | 0%         | 5%         | 5%         | %           | 5%            | 1%         | 9%         | 0%         | %           | 0%            | 0%         | 2%         | 6%         | 2%              |

Tab. S8. Results of the Mann-Whitney U tests for analysis and comparison of efficacy data.

| Compar                 | red data             |                            | U     | Dat   | aset |      |
|------------------------|----------------------|----------------------------|-------|---|------|------|
| Compar                 | ed data              | Statistic                  | valu  | si  | ze   | P    |
| A                      | В                    |                            | e     | A   | В    |      |
| λ-cyhalothrin 1X       | amitraz 1X efficacy, | Independent 2-group        | 203   |   |      | 3.22 |
| efficacy, overall      | overall              | Mann-Whitney $U$ test      | 9     | 80  | 82   | E-5  |
| λ-cyhalothrin 1X       | phoxim 1X efficacy,  | Independent 2-group        | 195   |   |      | 3.00 |
| efficacy, overall      | overall              | Mann-Whitney <i>U</i> test | 5.5   | 80  | 86   | E-4  |
| phoxim 1X efficacy,    | amitraz 1X efficacy, | Independent 2-group        | 332   | <   |      | 0.52 |
| overall                | overall              | Mann-Whitney $U$ test      | 4.5   | 86  | 82   | 3    |
| λ-cyhalothrin 2X       | λ-cyhalothrin 1X     | Independent 2-group        | 283   |   | \)   | 0.20 |
| efficacy, overall      | efficacy, overall    | Mann-Whitney $U$ test      | 0     | 80  | 80   | 7    |
| λ-cyhalothrin 4X       | λ-cyhalothrin 1X     | Independent 2-group        | 234   | $\backslash \!$ | •    | 0.00 |
| efficacy, overall      | efficacy, overall    | Mann-Whitney <i>U</i> test | 7     | 80  | 80   | 4    |
| λ-cyhalothrin 05X      | λ-cyhalothrin 1X     | Independent 2-group        | 351   |   |      | 0.28 |
| efficacy, overall      | efficacy, overall    | Mann-Whitney <i>U</i> test | ) / 2 | 80  | 80   | 8    |
| λ-cyhalothrin 025X     | λ-cyhalothrin 1X     | Independent 2-group        | 356   |   |      | 0.21 |
| efficacy, overall      | efficacy, overall    | Mann-Whitney <i>U</i> test | 6     | 80  | 80   | 2    |
| amitraz 2X efficacy,   | amitraz 1X efficacy, | Independent 2-group        | 423   |   |      | 0.00 |
| overall                | overall              | Mann-Whitney U test        | 7.5   | 82  | 82   | 4    |
| amitraz 4X efficacy,   | amitraz 1X efficacy, | Independent 2-group        | 453   |   |      | 5.74 |
| overall                | overall              | Mann-Whitney U test        | 3     | 81  | 82   | e-5  |
| amitraz 05X efficacy,  | amitraz 1X efficacy, | Independent 2-group        | 272   |   |      | 0.00 |
| overall                | overall              | Mann-Whitney <i>U</i> test | 7.5   | 81  | 82   | 49   |
| amitraz 025X efficacy, | amitraz 1X efficacy, | Independent 2-group        | 214   |   |      | 8.90 |
| overall                | overall              | Mann-Whitney <i>U</i> test | 6     | 81  | 82   | e-5  |
| phoxim 2X efficacy,    | phoxim 1X efficacy,  | Independent 2-group        | 442   |   |      | 0.02 |
| overall                | overall              | Mann-Whitney <i>U</i> test | 7     | 86  | 86   | 5    |
| phoxim 4X efficacy,    | phoxim 1X efficacy,  | Independent 2-group        | 486   |   |      | 9.62 |
| overall                | overall              | Mann-Whitney <i>U</i> test | 2.5   | 84  | 86   | E-5  |
| phoxim 05X efficacy,   | phoxim 1X efficacy,  | Independent 2-group        | 335   | 0.6   | 0.6  | 0.28 |
| overall                | overall              | Mann-Whitney <i>U</i> test | 2.5   | 86  | 86   | 9    |
| phoxim 025X efficacy,  | phoxim 1X efficacy,  | Independent 2-group        | 302   | 0.6   | 0.6  | 0.03 |
| overall                | overall              | Mann-Whitney <i>U</i> test | 5.5   | 86  | 86   | 9    |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X     | Independent 2-group        | 002   | <i></i>   | 25   | 0.00 |
| efficacy, 2008-2011    | efficacy, 2012-2015  | Mann-Whitney <i>U</i> test | 992   | 55  | 25   | 2    |
| λ-cyhalothrin 2X       | λ-cyhalothrin 2X     | Independent 2-group        | 100   | <i></i>   | 25   | 8.75 |
| efficacy, 2008-2011    | efficacy, 2012-2015  | Mann-Whitney <i>U</i> test | 8.5   | 55  | 25   | E-4  |
| λ-cyhalothrin 4X       | λ-cyhalothrin 4X     | Independent 2-group        | 991.  | <i></i>   | 2.5  | 0.00 |
| efficacy, 2008-2011    | efficacy, 2012-2015  | Mann-Whitney <i>U</i> test | 5     | 55  | 25   | 2    |
| λ-cyhalothrin 05X      | λ-cyhalothrin 05X    | Independent 2-group        | 972.  | <i></i>   | 2.5  | 0.00 |
| efficacy, 2008-2011    | efficacy, 2012-2015  | Mann-Whitney <i>U</i> test | 5     | 55  | 25   | 3    |
| λ-cyhalothrin 025X     | λ-cyhalothrin 025X   | Independent 2-group        | 004   |   | 2.5  | 0.01 |
| efficacy, 2008-2011    | efficacy, 2012-2015  | Mann-Whitney <i>U</i> test | 924   | 55  | 25   | 4    |
| amitraz 1X efficacy,   | amitraz 1X efficacy, | Independent 2-group        | 107   | <i></i>   | 27   | 0.00 |
| 2008-2011              | 2012-2015            | Mann-Whitney <i>U</i> test | 3.5   | 55  | 27   | 1    |
| amitraz 2X efficacy,   | amitraz 2X efficacy, | Independent 2-group        | 104   | 55  | 27   | 0.00 |
| 2008-2011              | 2012-2015            | Mann-Whitney <i>U</i> test | l     | 55  | 27   | 3    |
| amitraz 4X efficacy,   | amitraz 4X efficacy, | Independent 2-group        | 103   | 54  | 27   | 0.00 |

| 2008-2011              | 2012-2015              | Mann Whitney II test       | 8.5                 |                                 |     | 2    |
|------------------------|------------------------|----------------------------|---------------------|---------------------------------|-----|------|
|                        |                        | Mann-Whitney $U$ test      |                     |                                 |     |      |
| amitraz 05X efficacy,  | amitraz 05X efficacy,  | Independent 2-group        | 110                 | <i>-</i> 4                      | 27  | 1.68 |
| 2008-2011              | 2012-2015              | Mann-Whitney <i>U</i> test | 3.5                 | 54                              | 27  | E-4  |
| amitraz 025X efficacy, | amitraz 025X efficacy, | Independent 2-group        | 100                 | - 1                             | 2.5 | 0.00 |
| 2008-2011              | 2012-2015              | Mann-Whitney <i>U</i> test | 5                   | 54                              | 27  | 5    |
| phoxim 1X efficacy,    | phoxim 1X efficacy,    | Independent 2-group        | 712.                |                                 |     | 0.43 |
| 2008-2011              | 2012-2015              | Mann-Whitney <i>U</i> test | 5                   | 59                              | 27  | 6    |
| phoxim 2X efficacy,    | phoxim 2X efficacy,    | Independent 2-group        | 804.                |                                 |     | 0.94 |
| 2008-2011              | 2012-2015              | Mann-Whitney <i>U</i> test | 5                   | 59                              | 27  | 4/   |
| phoxim 4X efficacy,    | phoxim 4X efficacy,    | Independent 2-group        |                     | <                               |     | 0.30 |
| 2008-2011              | 2012-2015              | Mann-Whitney <i>U</i> test | 878                 | 59                              | 27  | V    |
| phoxim 05X efficacy,   | phoxim 05X efficacy,   | Independent 2-group        | 615.                | $\langle \rangle_{\prime}$      |     | 0.09 |
| 2008-2011              | 2012-2015              | Mann-Whitney <i>U</i> test | 5                   | 59                              | 27  | 1    |
| phoxim 025X efficacy,  | phoxim 025X efficacy,  | Independent 2-group        | $\langle C \rangle$ | $\backslash \backslash \rangle$ | ·   | 0.09 |
| 2008-2011              | 2012-2015              | Mann-Whitney <i>U</i> test | 619                 | )59                             | 27  | 7    |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X       | Independent 2-group        |                     |                                 |     | 0.61 |
| efficacy, 2008         | efficacy, 2009         | Mann-Whitney <i>U</i> test | 24.5                | 4                               | 15  | 7    |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X       | Independent 2-group        | 167.                |                                 |     | 0.95 |
| efficacy, 2009         | efficacy, 2010         | Mann-Whitney $U$ test      | 5                   | 15                              | 22  | 1    |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X       | Independent 2-group        | 141.                |                                 |     | 0.69 |
| efficacy, 2010         | efficacy, 2011         | Mann-Whitney <i>U</i> test | 5                   | 22                              | 14  | 6    |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X       | Independent 2-group        | 3                   |                                 | 1.  | 0.01 |
| efficacy, 2011         | efficacy, 2012         | Mann-Whitney <i>U</i> test | 12                  | 14                              | 6   | 5    |
| <u> </u>               |                        |                            | 12                  | 14                              | O   |      |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X       | Independent 2-group        | 12.5                | (                               | (   | 0.52 |
| efficacy, 2012         | efficacy, 2013         | Mann-Whitney $U$ test      | 13.5                | 6                               | 6   | 1    |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X       | Independent 2-group        | 2.1                 | _                               | 0   | 0.60 |
| efficacy, 2013         | efficacy, 2014         | Mann-Whitney <i>U</i> test | 31                  | 6                               | 9   | 0.68 |
| λ-cyhalothrin 1X       | λ-cyhalothrin 1X       | Independent 2-group        |                     |                                 |     | 0.93 |
| efficacy, 2014         | efficacy, 2015         | Mann-Whitney <i>U</i> test | 17                  | 9                               | 4   | 9    |
| amitraz 1X efficacy,   | amitraz 1X efficacy,   | Independent 2-group        |                     |                                 |     | 0.04 |
| 2008                   | 2009                   | Mann-Whitney <i>U</i> test | 50                  | 4                               | 15  | 6    |
| amitraz 1X efficacy,   | amitraz 1X efficacy,   | Independent 2-group        | 190.                |                                 |     | 0.43 |
| 2009                   | 2010                   | Mann-Whitney <i>U</i> test | 5                   | 15                              | 22  | 8    |
| amitraz 1X efficacy,   | amitraz 1X efficacy,   | Independent 2-group        |                     |                                 |     | 0.05 |
| 2010                   | 2011                   | Mann-Whitney <i>U</i> test | 93.5                | 22                              | 14  | 1    |
| amitraz 1X efficacy,   | amitraz 1X efficacy,   | Independent 2-group        |                     |                                 |     | 0.02 |
| 2011                   | 2012                   | Mann-Whitney <i>U</i> test | 80                  | 14                              | 7   | 3    |
| amitraz 1X efficacy,   | amitraz 1X efficacy,   | Independent 2-group        |                     |                                 |     | 0.22 |
| ( 2012                 | 2013                   | Mann-Whitney U test        | 30                  | 7                               | 6   | 4    |
| amitraz 1X efficacy,   | amitraz 1X efficacy,   | Independent 2-group        |                     |                                 |     | 0.85 |
| 2013                   | 2014                   | Mann-Whitney <i>U</i> test | 25                  | 6                               | 9   | 9    |
| amitraz 1X efficacy,   | amitraz 1X efficacy,   | Independent 2-group        |                     |                                 |     | 0.94 |
| 2014                   | 2015                   | Mann-Whitney $U$ test      | 23.5                | 9                               | 5   | 7    |
| phoxim 1X efficacy,    | phoxim 1X efficacy,    | Independent 2-group        |                     |                                 |     | 0.32 |
| 2008                   | 2009                   | Mann-Whitney $U$ test      | 58                  | 6                               | 15  | 5    |
| phoxim 1X efficacy,    | phoxim 1X efficacy,    | Independent 2-group        | 148.                |                                 |     | 0.37 |
| 2009                   | 2010                   | Mann-Whitney $U$ test      | 5                   | 15                              | 24  | 0    |
| phoxim 1X efficacy,    | phoxim 1X efficacy,    | Independent 2-group        | -                   | -                               |     | 0.77 |
| 2010                   | 2011                   | Mann-Whitney <i>U</i> test | 158                 | 24                              | 14  | 3    |
| phoxim 1X efficacy,    | phoxim 1X efficacy,    | Independent 2-group        | -50                 | - •                             |     | 0.57 |
| 2011                   | 2012                   | Mann-Whitney <i>U</i> test | 57                  | 14                              | 7   | 4    |
| 2011                   | 2012                   | indini willing o test      | 51                  | 1 1                             | ,   | •    |

| phoxim 1X efficacy, | phoxim 1X efficacy, | Independent 2-group   |    |   |   | 0.94 |
|---------------------|---------------------|-----------------------|----|---|---|------|
| 2012                | 2013                | Mann-Whitney $U$ test | 22 | 7 | 6 | 3    |
| phoxim 1X efficacy, | phoxim 1X efficacy, | Independent 2-group   |    |   |   | 0.24 |
| 2013                | 2014                | Mann-Whitney $U$ test | 37 | 6 | 9 | 8    |
| phoxim 1X efficacy, | phoxim 1X efficacy, | Independent 2-group   |    |   |   | 0.00 |
| 2014                | 2015                | Mann-Whitney $U$ test | 43 | 9 | 5 | 7 /  |

1X: field concentrations ( $\lambda$ -cyhalothrin was 0.5 g/L, and 1X phoxim was 2 g/L);

2X: 1 g/L  $\lambda$ -cyhalothrin, 1 g/L amitraz and 4 g/L phoxim;

4X: 2 g/L  $\lambda$ -cyhalothrin, 2 g/L amitraz and 8 g/L phoxim;

0.5X: 0.25 g/L  $\lambda$ -cyhalothrin, 0.25 g/L amitraz and 1 g/L phoxim;

0.25X: 0.125 g/L  $\lambda$ -cyhalothrin, 0.125 g/L amitraz and 0.5 g/L phoxim).

